Publications in collaboration with researchers from University College London (17)

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  2. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

2021

  1. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

2019

  1. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation: A Report from the GARFIELD-AF Registry

    JAMA Cardiology, Vol. 4, Núm. 6, pp. 526-548

  2. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

    Thrombosis Journal, Vol. 17, Núm. 1

  3. Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry

    Journal of the American Heart Association, Vol. 8, Núm. 3

  4. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

    American Heart Journal, Vol. 213, pp. 35-46

2018

  1. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry

    European Heart Journal, Vol. 39, Núm. 6, pp. 464-473

  2. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

    PLoS ONE, Vol. 13, Núm. 1

  3. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

    Indian Heart Journal, Vol. 70, Núm. 6, pp. 828-835

2017

  1. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation

    Heart, Vol. 103, Núm. 4, pp. 307-314

  2. Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: Contemporary perspective from the GARFIELD-AF registry

    BMJ Open, Vol. 7, Núm. 3

  3. Improved risk stratification of patients with atrial fibrillation: An integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

    BMJ Open, Vol. 7, Núm. 12

2016

  1. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists

    British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623

  2. Quality of vitamin k antagonist control and 1-year outcomes in patients with atrial fibrillation: A global perspective from the GARFIELD-AF registry

    PLoS ONE, Vol. 11, Núm. 10

  3. Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

    European Heart Journal, Vol. 37, Núm. 38, pp. 2882-2889